Clinical trials
Urothelial Bladder Cancer clinical trials
Below are recruiting urothelial bladder cancer clinical trials, each written for real people, not researchers. We’re tracking 213 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04106115RecruitingPhase 1/Phase 2
Durvalumab vaccine trial for high-risk bladder cancer after BCG
This early-phase trial tests durvalumab given with an experimental bladder cancer vaccine to help stop or slow high-risk bladder cancer that did not respond to or cannot be treated with BCG. It also evaluates safety and how well the treatment works in this setting.
CambridgeAges 18 years+ - NCT04235777RecruitingPhase 1
Immunotherapy plus radiation for metastatic non-prostate genitourinary cancers
This Phase 1 study tests a new immunotherapy drug (bintrafusp alfa) alone or combined with another investigational antibody drug, plus stereotactic body radiation (SBRT), to treat metastatic genitourinary cancers that are not prostate cancer. It aims to find the safest dose and to see whether the combination can shrink tumors.
Bethesda, MarylandAges 18–120 - NCT04574960RecruitingPhase 3
Neoadjuvant chemotherapy before kidney/ureter cancer surgery
This Phase 3 trial studies giving cisplatin-based chemotherapy before surgery for certain newly diagnosed upper-urinary-tract urothelial cancers (kidney/ureter). It may help shrink the cancer and improve outcomes by treating microscopic disease earlier.
Ottawa, OntarioAges 18 years+ - NCT04724018RecruitingPhase 1/Phase 2
Enfortumab and sacituzumab for metastatic bladder cancer
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT04878029RecruitingPhase 1
Cabozantinib plus enfortumab for advanced bladder cancer after immunotherapy
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
Atlanta, GeorgiaAges 18 years+ - NCT04923178Recruiting
Natural history study of bladder and other genital cancers
This study follows people with urothelial cancer and certain rare genital (genitourinary) cancers over time to learn how these diseases progress. It may help researchers understand patterns of symptoms and outcomes, even if it is not a drug trial.
Bethesda, MarylandAges 18 years+ - NCT04970472Recruiting
Urothelial bladder cancer sample collection for adults
This trial collects clinical samples from adults who have suspected or confirmed urothelial (bladder/urinary tract lining) cancer. It helps researchers study the disease and may support future improvements in diagnosis or treatment.
ToulouseAges 18–99 - NCT05037279RecruitingPhase 3
Testing BCG treatment for bladder cancer after full tumor removal
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
Vancouver, British ColumbiaAges 18 years+ - NCT05072600RecruitingPhase 2
Pembrolizumab after complete bladder cancer treatment response
This trial studies pembrolizumab (an immunotherapy) in people with muscle-invasive bladder cancer who had a combined “trimodality” treatment and then achieved a complete response. The goal is to help control the cancer after the initial treatment is finished.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05296564RecruitingPhase 1/Phase 2
TCR cell therapy for NY-ESO-1 positive metastatic cancers
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
JerusalemAges 18–70 - NCT05312671RecruitingPhase 2
Atezolizumab plus chemo for small cell bladder cancer
This trial studies whether a drug called atezolizumab combined with chemotherapy (etoposide and a platinum drug) can shrink or control small cell bladder cancer. It may help by boosting the immune system against the cancer while the chemotherapy treats fast-growing cancer cells.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05337189Recruiting
Urine DNA test study for possible bladder cancer
This trial looks at how a urine DNA test may help find bladder cancer (or clues that it might be present), especially in people with symptoms or higher risk. You may be asked to provide urine and also complete standard tests like imaging, a cystoscopy, or pathology checks.
Beijing, Beijing MunicipalityAges Any age - NCT05562791RecruitingPhase 1
Testing PSMA PET/CT scans for metastatic bladder or skin cancer
This Phase 1 study tests how well a PSMA PET/CT scan can find cancer spots in people with metastatic bladder cancer (urothelial cancer) or metastatic melanoma. It may help doctors better see where cancer is and guide next steps.
Basking Ridge, New JerseyAges 18 years+ - NCT05646485Recruiting
Bladder cancer screening for people at higher risk
This trial tests screening for bladder cancer in people who have higher risk due to age, smoking, and certain job exposures. It may help find bladder cancer earlier when treatment can be more effective.
Dallas, TexasAges 50 years+ - NCT05656235RecruitingPhase 2
Study of keeping kidneys longer in upper tract bladder cancer
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT05962541RecruitingPhase 4
Using bladder scans to plan repeat surgery for bladder cancer
This trial checks whether a bladder scan and score (VI-RADS from MRI) can help doctors choose the right way to do a second look surgery for non-muscle-invasive bladder cancer. The goal is to reduce the chance of needing extra (“secondary”) resections while still catching important disease early.
Rome, LazioAges 18 years+ - NCT05982561Recruiting
Testing a urine test for bladder cancer recurrence
This trial tests a new urine test (BCDx) to see if it can catch bladder cancer coming back in people with non-muscle invasive bladder cancer (NMIBC) who are already having regular check-ups. You would give a urine sample before your routine cystoscopy, and the results may help doctors monitor your cancer more easily.
Little Rock, ArkansasAges 18 years+ - NCT06026189Recruiting
Reducing cystoscopy for blood in urine
This trial tests if we can safely skip a bladder camera test (cystoscopy) for people who have microscopic blood in their urine. If you meet certain criteria, you may not need the procedure.
RotterdamAges Any age - NCT06040762Recruiting
Get moving before bladder cancer surgery
This study tests whether a home-based exercise program before surgery can help improve physical function in people with bladder or upper tract urothelial cancer. If you are planning to have surgery to remove your bladder or upper urinary tract, you may be able to join.
Seattle, WashingtonAges 18 years+ - NCT06092450Recruiting
Using AI scans to predict bladder cancer treatment results
This trial uses an artificial intelligence model to analyze CT scans taken before bladder removal surgery. The goal is to see if the AI can predict outcomes for patients with muscle-invasive bladder cancer.
Chongqing, Chongqing MunicipalityAges Any age - NCT06138561Recruiting
Bladder cancer treatment study for older adults
This study looks at how well different treatments work for older adults with bladder cancer that has spread and who cannot take cisplatin. It also checks if geriatric assessments help guide care.
Boston, MassachusettsAges 65 years+ - NCT06167356Recruiting
Bladder cancer relapse and quality of life study after TURBT
This study tracks patients with early-stage bladder cancer after surgery (TURBT) to see how often the cancer returns and how it affects your daily life.
Milan, MIAges 18 years+ - NCT06170177Recruiting
Life after bladder removal surgery study
This study looks at how people feel and their health after having their bladder removed. It aims to understand quality of life after this surgery.
Milan, MIAges 18 years+
Hear when a new Urothelial Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for urothelial bladder cancer?
- Yes. Clin2 currently lists 213 recruiting urothelial bladder cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a urothelial bladder cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a urothelial bladder cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.